

[Click here to view linked References](#)

1 Longevity of daily oral Vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D
2 observed 2 years after cessation of a 1-year randomized controlled trial (VICtORy RECALL).
3
4
5
6
7

8 Macdonald HM¹, Gryka A², Tang JCY³, Aucott LS¹, Fraser WD³, Wood AD¹
9

10
11
12
13 ¹School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK ²Obesity Action
14 Scotland, Glasgow, UK ³ Medical School, University of East Anglia, Norwich Research Park, Norwich,
15
16
17
18 UK
19
20
21
22
23
24
25
26

27 Corresponding author
28
29
30
31
32

33 Helen Macdonald (Emeritus professor)
34

35
36 School of Medicine, Medical Sciences and Nutrition
37

38
39 University of Aberdeen
40

41 Foresterhill
42

43
44 Aberdeen
45

46
47 AB25 2ZD
48
49
50
51

52 Helen Macdonald, Anna Gryka, Jonathan Tang, Lorna Aucott LS, William Fraser and Adrian Wood
53

54 declare that they have no conflicts of interest
55
56
57
58
59
60
61
62
63
64
65

Mini Abstract

To determine how long vitamin D lasts after supplementation ceases, the marker of status was measured 2 and 3 years after a 1 year trial. Compared to placebo, the proportion of vitamin D-deficient women was still lower, if they had taken daily vitamin D3, after 2 years, indicating its longevity.

Abstract

Purpose

To determine longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 3 years after a 1-year randomised, double-blind placebo controlled trial; and to investigate possible predictive factors.

Method

Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), who had not taken vitamin D supplements since the trial ended, were invited to attend follow up visits. Total 25-hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the original RCT samples were re-analysed simultaneously. Vitamin D binding protein (VDBP) was measured by monoclonal immunoassay.

Results

In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) re-attended, equally distributed between the original treatment groups: daily vitamin D3 400IU; 1000IU; and placebo. One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15%,0%, 0% (Chi-square $p<0.001$, $n=46,44,54$). After 2 years (March 2012) it was 22%, 4%, 4% ($p=0.002$, $n=50,48,57$); after 3 years 23%, 13%, 15% ($p=0.429$, $n=48,45,52$). The respective proportions of women with 24,25OH2D < 2.2 nmol/L were 50%, 2%, 2% (1 month, $p>0.001$, $n=46,44,54$); 42%, 33%, 12% (2y,

1 p=0.002,n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,45,51,). VDBP was a predictor of
2 circulating 25OHD longevity (beta for VDBP in µg/ml:0.736; 95% CI 0.216-1.255,p=0.006) but not
3
4 24,25OH₂D.
5
6

7 **Conclusion**
8
9

10 400 IU (or 1000 IU) daily vitamin D₃ showed benefits over placebo 2 years after supplementation
11
12 ceased, in keeping 25OHD >25 nmol/L.
13
14

15
16 KEY WORDS: Daily vitamin D, 25-hydroxyvitamin D, 24,25-dihydroxy vitamin D, RCT, longevity,
17
18 postmenopausal women
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

INTRODUCTION

1
2
3 Vitamin D continues to be the subject of controversy with regard to health outcomes^{1,2}, and the
4
5 exponential increase in often inappropriate testing of 25-hydroxyvitamin D [25OHD], for assessing
6
7 vitamin D status, continues to be a burden on health resources³. Whereas population observational
8
9 studies suggest a beneficial association between vitamin D status and many health outcomes, more
10
11 recent intervention studies have been less convincing⁴. A number of other structured literature
12
13 reviews and meta-analyses have been performed with mixed conclusions^{1,5-7}. Government
14
15 evaluations of the evidence have concluded that only in the case of musculoskeletal health is the
16
17 role of vitamin D well-founded⁸⁻¹⁰.

18
19
20
21
22
23 Lack of sunlight for cutaneous synthesis of vitamin D; and the limited amount of vitamin D present
24
25 naturally in the diet; lie behind concerns about vitamin D deficiency in Northern Europe and the US.
26
27 The past assumption that vitamin D made in the summer lasted over the winter months¹¹ has
28
29 largely been dismissed on the basis of the half-life of circulating 25OHD being only a few weeks¹².
30
31 Yet the half-life estimates of 25OHD are based on extrapolation of data from short-term studies^{13,14}
32
33 and there are no measured long-term data on the longevity of vitamin D following cessation of
34
35 supplementation. The Scientific Advisory Committee of Nutrition (SACN) recommended a reference
36
37 nutrient intake (RNI) of 400 IU daily vitamin D for all adults in the UK⁹, compared to 600IU being
38
39 recommended in the US and Europe^{8,10}.

40
41
42
43
44
45 'Vitamin D' intervention and dosing studies have consistently shown that the lower the starting
46
47 25OHD the greater the increase^{15,16}; and progressively higher doses of vitamin D result in smaller
48
49 incremental increases in 25OHD^{17,18}. It is uncertain whether additional vitamin D is incompletely
50
51 absorbed, or metabolised more quickly and excreted, suggesting that there is no benefit to taking
52
53 higher doses; or whether it is stored (or converted to other metabolites that are either stored, or
54
55 protected from degradation), allowing additional amounts to be used in the future. The role of
56
57 vitamin D binding protein (VDBP) in binding 25OHD has been suggested as one way that 25OHD is
58
59
60
61

1 protected from degradation ¹⁹. Most research on VDBP has focussed on adjusting 25OHD for VDBP in
2 the belief that it is free, not total, 25OHD that is associated with health outcomes ²⁰. Criticisms have
3
4 been raised regarding the limited data available for the equations used to estimate free 25OHD, and
5
6 the monoclonal immunoassay used to measure VDBP ²¹.
7
8
9

10 Although it is only 1,25 dihydroxyvitamin D that has biological activity (circulating at concentrations
11 of pmol/L and under homeostatic control), and 25OHD that is the accepted marker of status; there is
12 interest in other vitamin D metabolites, particularly 24,25 dihydroxyvitamin D (24,25OH₂D) with
13 research focusing mainly on its interference in the measurement of 25OHD ²². This metabolite,
14 which circulates at 1/13 of the concentration of 25OHD, is the first step on the degradation pathway
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

23 but what role, if any, it might play in health is unknown. There are few data on the status of
different vitamin D metabolites especially from intervention studies ^{24,25}.

The VICtORy (VItamin D and CardiOvascular Risk) RCT in 2009-10 had all participants starting at the
beginning of the year, when 25OHD is at its lowest in the UK, allowing direct bimonthly comparison
between the treatment and placebo groups throughout the year. It found that there was no effect of
daily vitamin D₃ treatment (400 IU or 1000 IU) on conventional markers of cardiovascular risk at any
point ²⁶. Bone mineral density (BMD) scans taken at the start and end of the study, showed that hip
bone loss was reduced in the group taking 1000IU daily vitamin D, but not in the 400IU group,
although the difference in 25OHD increase between the two groups was small ¹⁸. The aim of this
RECALL study was to determine the longevity of vitamin D supplementation, by testing for
differences in the proportion of women with 25OHD < 25 nmol/L, and any differences in 24,25
dihydroxyvitamin D (24,25OH₂D), two and three years after the VICtORy study intervention phase
had ended; and to determine possible predictive factors associated with better vitamin D status.

METHODS

Population and participant involvement

The women in this study were healthy non-smoking postmenopausal women mean age (SD) 64.7 (2.1) y who had taken part in a placebo controlled randomized controlled trial of vitamin D3 between January 2009 and February 2010²⁶ and attended a 'decay visit' in March 2010, 1 month after study completion. The results of the VICTORY RCT, which showed no difference in markers of cardiovascular risk, inflammation, or glucose tolerance after 1 year between the 2 treatment groups (400 IU and 1000 IU daily vitamin D3) and placebo; and an identical seasonal decrease on blood pressure for the 3 groups, were presented to the volunteers (n=287 of 305 who took part) at one of three presentations. The BMD data were not available for dissemination. The formal presentation was followed by an informal lunch with the researchers, and the opportunity to ask questions. It meant that when the women were recalled in 2012 most had not taken vitamin D supplements since the study ended. We anticipated that one half the women originally randomised would be willing and eligible to return (n 152). Some women were taking cod liver oil capsules containing < 5 µg (200 IU) vitamin D3 a day and this was adjusted for in the statistical analysis. A group of 3 VICTORY RCT participants advised on the RECALL study design prior to its implementation, in particular their opinions on wearing UV exposure badges. Ethical approval for the RECALL study was provided by North of Scotland Research Ethics Committee (12/NS/0013), and all women gave informed consent.

RECALL visits

Women were invited to attend additional visits in March 2012 and March 2013 (two years and three years after the original trial had ended). Those who agreed to take part (n=159, mean [SD] age 67.6 [2.3] y), confirmed that they had not taken vitamin D supplements since the study ended and were not intending to take extended holidays abroad. A flow diagram showing the numbers of women at the start and end of the original RCT, and the numbers in the RECALL study is shown in Figure 1. At

1 both RECALL visits the women were weighed on calibrated weighing scales (Tanita Europe BV,
2 Amsterdam, The Netherlands), their height measured by stadiometer (Holtain Ltd Crymych UK), and
3
4 blood pressure measured using a Omron 705CP sphygmomanometer (Omron, Herts UK). Lean and
5
6 fat body mass was obtained from whole body scans at the final RCT visit (V6) using dual energy X-ray
7
8 absorptiometry (DXA; Lunar iDXA, GE Medical Systems Inc, Madison, WI) and a blood sample was
9
10 taken for measurement of 25OHD. As a result of changes in analytical procedure to remove
11
12 artefacts, the samples were analysed together with re-analysis of the original study samples. The
13
14 researchers seeing the volunteers and analysing the data; and the laboratory carrying out the
15
16 analysis remained blind to the intervention groups.
17
18
19
20
21
22

23 Diet had been assessed by food frequency questionnaire at 2-monthly intervals during the VICTORY
24
25 trial ²⁶. The women again completed the FFQ at the first RECALL visit (March 2012). In March 2013,
26
27 those whose diet had changed in the previous year completed an additional FFQ. Any vitamin D
28
29 obtained from cod liver oil was added to the dietary vitamin D.
30
31
32

33
34 At each visit, skin colour was measured at the forearm, and left and right cheekbones using a hand-
35
36 held chromameter (CM-2600d spectrophotometer; Konica Minolta Photo Imaging (UK) Ltd.,
37
38 Feltham, UK). The measurements obtained for L*(dark-light) and b*(blue yellow) axes of colour were
39
40 used to estimate the individual topology angle (ITA, an indication of melanin pigment in the skin
41
42 where the higher the ITA, the lighter the skin colour) according to the following equation $ITA =$
43
44 $[\arctangent(L^* - 50)/b^*] \times 180/\pi$ ²⁷. The women also reported their skin type ²⁸.
45
46
47
48
49

50 In between the two RECALL visits the women were sent badges every month, to wear for 1 week to
51
52 assess UV radiation exposure, which they returned by post. The UVB badges were disposable, made
53
54 of polysulphone film; one was worn for 3 days and replaced by a second one on day 4 for the rest of
55
56 the week. The absorbance at 330nm of the polysulphone badge was measured using a
57
58 spectrophotometer (Perkin-Elmer UV/VIS Lambda 2 spectrophotometer) before and after wearing
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

($\Delta A330$), and converted to standard erythemal dose (SED) using the equation: $SED = 10.7(\Delta A330) + 14.3(\Delta A330)^2 - 26.4(\Delta A330)^3 + 89.1(\Delta A330)^4$ ²⁹. One SED is equivalent to 100 J/m² UV radiation exposure. The SED estimates from each badge were summed to obtain the weekly total. Typically, a person would receive 1 SED/ day UV exposure during the summer in Aberdeen³⁰. A subset of women also wore UVA badges (purchased from Scienterra Ltd, Oamaru, NZ), which were electronic devices that continuously recorded data. Algorithms (written by Maciej Gryka) were used to extract the data collected during the week they were worn by the volunteers. The badges had been calibrated with the assistance of Dr Martin Allen (Health Protection Agency, Cambridge) enabling the readings to be converted to SED equivalents. At the final visit women provided details about holidays to sunny destinations during the previous year, for testing in the statistical models. Women were also asked if they had been away for >1 month between the end of VICTORY RCT and the start of the RECALL study, and a sensitivity analysis was done excluding these women.

Laboratory Measurements

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Circulating vitamin D metabolites and parathyroid hormone (PTH) were measured at the University of East Anglia. 25OHD3, 25OHD2, 24,25OH2D3 and 24,25OH2D2 were measured simultaneously by a published liquid chromatograph tandem mass spectrometry (LC-MS/MS) method²⁵. In brief, 100 μ L of sample spiked with [2H6]-24,25-OH2D3 and [2H6]-25OHD3 as internal standards was extracted using supported liquid extraction (SLE) for removal of phospholipids followed by derivatisation with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) to enhance ionisation efficiency. Measurements of 25OHD3 were calibrated using commercial 25OHD3 standard materials (Chromsystems, M \ddot{u} nchen, Germany) that were traceable to reference source NIST SRM972a. The inter-assay CV for 25OHD3 and 25OHD2 were $\leq 9\%$ across the analytical range between 0-200 nmol/L, with lower limit of quantification (LLOQ) at 0.1 nmol/L. Mean assay recovery was $96 \pm 2\%$. Vitamin D external quality control (DEQAS) returns showed the accuracy bias of 25OHD3 measurements against NIST reference method was $< 8\%$. Measurements of 24,25OHD3 and 24,25OHD2 were calibrated using commercially

1 certified standard materials spiked into human based vitamin D-depleted serum. The inter-assay CVs
2 were <10% across the analytical range between 0-25 nmol/L, with LLoQ at 0.1 nmol/L. Mean assay
3
4 recovery was 97 ±4%. DEQAS returns on 24,25OH2D3 showed a 2% bias against all laboratory
5
6 trimmed mean. PTH was measured in plasma samples using an electrochemiluminescent
7
8 immunoassay (ECLIA) on a Modular Analytics E170 analyzer (Roche Diagnostics, Burgess Hill, UK).
9
10 Inter/intra-assay coefficient of variation was <4% from 1 to 30 pmol/L. The assay sensitivity
11
12 (replicates of the zero standard) was 0.8 pmol/L.
13
14
15
16
17
18

19 Vitamin D Binding Protein (VDBP)

20
21
22 VDBP was measured in Aberdeen using a monoclonal enzyme-linked immunosorbent assay (Human
23
24 vitamin D BP QuantikineELISA Kit; R&D Systems, Oxford, UK) according to the manufacturer's
25
26 instructions. The inter-/intra-assay CV was <7.4 and <6.2%, respectively, across the working range.
27
28
29
30

31 Statistical analysis

32
33
34 All analyses were done using SPSS version 24 with pre-planned analysis. Dependent variables were
35
36 transformed using the natural logarithm (Ln) if required. Independent t-tests were used to check the
37
38 characteristics between RECALL participants and those who did not take part. Chi square tests were
39
40 used to test differences in the number of women with 25OHD < 25 nmol/L and 24,25OH2D < 2.2
41
42 nmol/L (the threshold equivalent to 25 nmol/L 25OHD) between treatment groups. Linear
43
44 regression was used to relate the 25OHD measurements obtained by the two different tandem mass
45
46 spectrometry procedures (original and modified de-lipidation method). Repeated measures ANOVA
47
48 was performed for testing differences in vitamin D metabolites and PTH according to study visit and
49
50 treatment group; and to detect any differences in monthly sunlight exposure during 2012-3,
51
52 between treatment groups. Mixed model analysis was undertaken to determine the predictors of
53
54 25OHD and 24,25OH2D at the RECALL visits (2-visit model). A 4-visit model compared the last four
55
56
57
58
59
60
61
62
63
64
65

1 vitamin D metabolite measurements (at the end of the VICtORy intervention, 1 month later, 2y later,
2 and 3y later). Both models tested factors that might influence the change in vitamin D metabolites
3
4 (treatment group, use of cod liver oil supplements, lean body mass, fat mass, passive smoking,
5
6 dietary vitamin D and other nutrients [vitamin A, preformed retinol, calcium, protein, fat,
7
8 carbohydrate and energy], sunlight behaviour, holidays abroad, skin type, VDBP). There were few
9
10 data points missing for the main mixed model and the missing data were assumed to be missing
11
12 completely at random.
13
14
15
16
17
18

19 RESULTS

20
21
22 Of the 265 women who completed VICtORY, 236 responded (89%): 43 (16%) taking > 400 IU daily
23
24 vitamin D (some prescribed supplements as an adjunct to osteoporosis treatment) were excluded;
25
26 25 were unable (other commitments, travel, or unknown); and 9 responded positively after the
27
28 deadline (Figure 1). A total of 159 women attended the RECALL visits (n=52, n=49, n=58, respectively
29
30 for placebo, 400 IU, and 1000 IU- vitamin D treatment groups). There were no differences in
31
32 characteristics according to their original treatment allocation except for VDBP, where mean [SD]
33
34 was significantly higher for the 400IU group (296 [44]µg/ml) compared to 1000 IU (244 [89]µg/ml)
35
36 (post hoc ANOVA p=0.02) (Table 1). There were no differences between the women attending and
37
38 not attending the RECALL study, in terms of age, height, and starting vitamin D status, but those who
39
40 took part were slightly heavier (Supplementary Table 1).
41
42
43
44
45
46

47 *Comparison of 25OHD obtained by the original tandem mass spectrometry method with a modified* 48 *method that included a de-lipidation procedure*

49
50
51
52 The results of 25OHD using the original method have been reported previously²⁶. The de-lipidation
53
54 step introduced for the 25OHD measurements, reported here, resulted in greater recovery of
55
56 25OHD. An equation relating the two was obtained by linear regression analysis:
57
58
59
60
61
62
63
64
65

$$\ln(25\text{OHD with delipidation}) = 0.859 \times \ln(25\text{OHD without delipidation}) + 0.773 \quad (R=0.904)$$

1
2
3 The modified method gave higher mean (SD) 25OHD concentrations (n=2032 measurements for
4 comparison: Total 25OHD: 68.6 (26.9) vs 55.4 (23.0) nmol/L; 25OHD2: 1.7 (1.1) vs 1.0 (1.4) nmol/L;
5
6
7 25OHD3: 66.9 (27.2) vs 54.4 (23.1) nmol/L), and fewer women with 25OHD < 25 nmol/L. The
8
9 percentages of women who took part in the RECALL study with 25OHD < 25 nmol/L at the start of the
10
11 RCT, using the original method was 34.6, 28.6 and 32.8 for placebo, 400 IU and 1000 IU respectively
12
13 (Chi-square p=0.802); whereas using the modified method it was 13.0, 8.2 and 12.7, respectively
14
15 (Chi-square p=0.694).
16
17
18
19
20

21 *Numbers of women below thresholds for 25OHD and 24,25OH2D*

22
23 The percentage of women with 25OHD < 25 nmol/L, and 24,25OH2D < 2.2 nmol/L at each visit are
24 shown in Figure 2. For the placebo group, the percentage with 25OHD < 25 nmol/L decreased
25
26 gradually at each visit until July-August (the only visit where no-one had 25OHD < 25 nmol/L) and
27
28 then gradually increased until the end of the study. For the treatment groups there was a rapid
29
30 increase in 25OHD so that no participant had 25OHD < 25 nmol/L after 2 months treatment, and
31
32 although mean 25OHD had decreased 1 month after the intervention ceased, no-one had fallen
33
34 below the 25 nmol/L threshold (Figure 2). One month after the RCT ended (March 2010) the
35
36 respective number of women in placebo, 400IU, and 1000IU vitamin D3 groups, with 25OHD < 25
37
38 nmol/L was 15%, 0%, 0% (p < 0.001, n=46, 44, 54). After 2 years (March 2012) it was 22%, 4%, 4%
39
40 (p=0.002, n=50, 48, 57); after 3 years 23%, 14%, 17% (p=0.429, n=48, 45, 52). Using the 24,25OH2D
41
42 marker, there was a similar pattern for the 2.2 nmol/L cut off. The respective number of women
43
44 with 24,25OH2D < 2.2 nmol/L was 50%, 2%, 2% (1 month, p > 0.001, n=46, 44, 54); 42%, 33%, 12% (2y,
45
46 p=0.002, n=50, 48, 57) and 45%, 27%, 29% (3y, p=0.138, n=47, 55, 51).
47
48
49
50
51
52
53
54
55

56 The mean circulating concentrations of 25OHD and 24,25OHD (Figure 3) had similar trajectories: the
57
58 placebo showing a marked season pattern with much lower circulating concentrations than either
59
60
61
62
63
64
65

1 treatment group, even in summer. There was little change in 1,25OH₂D and PTH (the latter two
2 analytes were collected at selected visits only) (Figure 3).
3

4 5 *Dietary vitamin D and sunlight* 6

7
8 Mean (SD) daily dietary intake of vitamin D was 5.1 (3.4) µg in both 2012 and 2013 (Table 1). Cod
9 liver oil was taken by 37 participants, averaging intake 1.2 (2.4) µg/d in these individuals and
10 increasing overall mean (SD) dietary vitamin D intake to 6.4 (4.1) µg/d.
11
12
13
14
15

16 The sunlight exposure of the subset of women who wore badges (supplementary figure 1) showed
17 similar monthly patterns for UVB and UVA, and no differences between treatment groups (repeated
18 measures ANOVA). The two variables were highly correlated (Spearman coefficient 0.7, P<0.001).
19
20
21
22
23

24 Women who had been on holiday abroad for longer than one month since the study finished (n 22)
25 had higher circulating 25OHD compared to the rest of the women (55.5[24.7] n=21 versus 46.2
26 [18.9] n=126), although not significant.
27
28
29
30
31

32 *Mixed model analysis of 25OHD and 24,25OH₂D measurements following the end of the VICtORy RCT* 33 34 35

36 The mixed model which included the last four 25OHD measurements (at the end of the intervention,
37 +1 m, +2y, and +3y) showed the time variable and the original study group to be significant
38 predictors of 25OHD. Dietary energy intake and VDBP were additional significant predictors, with
39 VDBP positively associated; and dietary energy negatively associated with 25OHD. Dietary vitamin D
40 and vitamin A were not associated with 25OHD. Although dietary fat, protein, carbohydrate and
41 dietary calcium intake appeared to be significant predictors of 25OHD, when tested independently,
42 the relationship disappeared when dietary energy was included, due to the correlation between
43 these macronutrients and dietary energy intake. Weight, height, age, sunlight behaviour, body fat
44 mass, and lean mass (collected at the end of the VICtORy intervention period¹⁸) were not significant
45 predictors of 25OHD (Table 2, Model 1).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The second model for the last two 25OHD measurements (2012 and 2013) tested skin colour, and
2 participants' sunlight behaviour, including the total number of days spent abroad on holiday
3
4 between the two visits. Again visit, treatment group and VDBP were significant predictors of 25OHD,
5
6 but not dietary energy intake. In this model the use of cod liver oil supplements, darker arm skin
7
8 colour, and number of days spent abroad indicated higher vitamin D status. (Table 2, Model 2a).
9

10
11 Finally a subset analysis in which there was more detailed information on sunlight exposure
12
13 obtained from wearing UV detection badges, showed that overall UVB (but not UVA) exposure was a
14
15 weak negative predictor of 25OHD (Table 2, Model 2b).
16
17

18
19 VDBP was not a predictor of 24,25(OH)2D (Table 2). Only 'holidays abroad' remained a positive
20
21 predictor in the final 4-visit model . For the 2-visit model, as for 25OHD, supplement use was a
22
23 positive predictor and there was a weak negative association with UVB and not UVA exposure.
24
25

26
27 For both vitamin D metabolites, there were significant associations with 1,25OHD (positive) and PTH
28
29 (negative) when these were added; but only with 1,25OH2D in the subset model 2b. Sensitivity
30
31 analysis excluding women abroad for longer than 1 month since the RCT finished showed no overall
32
33 differences except for PTH no longer being a significant predictor of 25OHD in the 4-visit model.
34
35

36
37 The characteristics of women below and above the thresholds at the final RECALL visit (when there
38
39 was no longer a difference between treatment groups) showed differences in 1,25(OH)2D and
40
41 25OHD before the RCT started, for 25OHD; and also supplement use for 24,25OH2D (supplementary
42
43 Table 2).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

DISCUSSION

1
2
3 We believe that this is the only long-term study to examine vitamin D status after completion of a
4
5 placebo-controlled RCT of low dose, daily vitamin D3. Our data, showing that vitamin D
6
7 supplementation is still evident 2-years but not 3-years after cessation, are consistent with a 1-year
8
9 single-arm study in 45 nursing home residents providing 5000 IU vitamin D daily from vitamin D-
10
11 fortified bread, which showed that 25OHD measured in 23 residents was higher compared to
12
13 baseline 1 year after the study (64.9 ± 24.8 nmol/L) but not 3 years (28.0 ± 15.0 nmol/L)³¹. They
14
15 support our longitudinal data over 3 years, indicating that for the majority, circulating 25OHD does
16
17 not decrease below a set minimum³⁰.
18
19
20
21

22
23 We hypothesise that during winter at high latitude, circulating 25OHD is prevented from decreasing
24
25 below a set point for a period, either being topped up from stores when required, or being
26
27 protected from degradation to some extent. It is only when the store or protected 25OHD has been
28
29 exhausted that people become at risk of vitamin D deficiency: when usage begins to outstrip
30
31 provision, and the conversion to 1,25OH2D becomes less efficient.
32
33
34

35
36 Although vitamin D stored in the body was considered important in maintaining 25OHD over
37
38 winter³², other evidence from pig models³³ suggest that the size of vitamin D stores is limited³⁴.
39

40
41 There is some uncertainty regarding the exact contribution that sunlight and diet provide to the
42
43 overall vitamin D economy^{35,36}, although direct observations show that 80%-90% 25OHD comes
44
45 from summer sunlight in the UK, with 25OHD increasing rapidly in summer, against a background
46
47 where dietary vitamin D remains constant³⁷. Depending on time of day, latitude and skin
48
49 pigmentation, 5 to 15 minutes exposure to summer UVB is required to make sufficient vitamin D³⁸
50
51 but it is unclear how much is stored long-term, compared to vitamin D from the diet. It is possible
52
53 there may be sunlight/ oral vitamin D interactions, as VICTORy treatment doses were not additive,
54
55 contributing less to total 25OHD in the summer, compared to autumn¹⁸.
56
57
58
59
60
61

1 VDBP was a factor affecting the half-lives of 25OHD2 and 25OHD3 ¹⁹. Our data suggest that VDBP
2 may play a minor role in extending the half-life of circulating 25OHD in this population, but it is likely
3
4 there must be other mechanisms which preserve 25OHD. VDBP was measured at one visit only
5
6 (March 2010, the same month as the two RECALL visits). The downside of the monoclonal
7
8 immunoassay in failing to detect other genotypes of VDBP ²¹ may be less relevant within a single
9
10 Caucasian population. It is possible that VDBP concentrations could change according to season, and
11
12 affect how much 25OHD is metabolised, but we cannot test that hypothesis in this study. Jamil *et al.*
13
14 found that VDBP was lower in spring compared to autumn in South East Asians living in Aberdeen,
15
16 UK ³⁹.

21
22 Other predictors were similar to those tested previously ³⁰. We did not find that individual dietary
23
24 vitamin D intake predicted vitamin D status, although use of cod liver oil capsules (providing an
25
26 additional 200 IU vitamin D) was important. The finding that darker skin colour, and holidays abroad
27
28 between the recall visits (2012-2013) were associated with greater 25OHD is in keeping with more
29
30 sunlight exposure leading to greater cutaneous synthesis of vitamin D. The weak negative
31
32 association between UVB exposure obtained from the badges and 25OHD was unexpected, but may
33
34 indicate some interaction between diet and sunlight as suggested earlier; or reflect that once
35
36 sufficient vitamin D is synthesised, spending longer outside will not result in more vitamin D ⁴⁰. The
37
38 benefit of holidays abroad and cod liver oil supplements has been noted in our cross-sectional and
39
40 longitudinal studies ^{41 42}. Three years after the RCT, 17% of participants had 25OHD < 25 nmol/L,
41
42 with the main difference between those below and above the cut-off being the 25OHD
43
44 measurement before the intervention started. Whether women revert to original behaviour after
45
46 taking supplements (eg sun avoidance, diet low in vitamin D) or there is genetic predisposition to
47
48 lower 25OHD⁴³ is unknown. Whatever the reason, our data show that small amounts of daily
49
50 vitamin D are effective in preventing deficiency in this group. Tracking of 25OHD over 10 years has
51
52 been noted in longitudinal studies ^{30,44}.

1 Comparing the metabolite 24,25(OH)2D with the established marker of status, 25OHD, showed
2 similar trajectories in response to supplementation, with perhaps a greater difference in
3
4 24,25(OH)2D response between 400IU and 1000IU vitamin D3 than for 25OHD, indicating a lower
5
6 25OHD:24,25OH2D ratio. This is consistent with observations that 25OHD:24,25OH2D ratios are
7
8 higher when 25OHD is < 50nmol/L ²⁵. The longer maintained increase in 24,25(OH)2D with 1000IU
9
10 vitamin D supplementation would indicate a different rate of metabolism or production from stores
11
12 for 24,25(OH)D compared to 25OHD. Unlike 25OHD, VDBP had no association with 24,25OHD
13
14 longevity. Although we tested 1,25(OH)2D and PTH as additional variables in the models, the
15
16 dependency is likely to be reversed, with 25OHD and 2425OH2D affecting 1,25(OH)2D positively and
17
18 PTH negatively.
19
20
21
22
23

24 The accepted 25OHD half-life of a few weeks has been based on extrapolation of short-term data ¹³.
25
26 If there are feed-back mechanisms that prevent the continued rate of decay beyond a set minimum,
27
28 these would be missed. If we had extrapolated 25OHD from our 1-month decay visit, which showed
29
30 a rapid initial decrease after treatment ceased, we would have concluded that any difference in
31
32 25OHD would have disappeared within months. Our measured data at two years show that was not
33
34 the case. Our findings indicate that it will be those who year-on-year do not get enough sunlight and
35
36 who do not reach the RNI who are going to suffer frank vitamin D deficiency, leading to symptoms;
37
38 as any protective mechanisms cannot keep going indefinitely.
39
40
41
42
43

44 SACN's risk assessment concluded that, as it could not recommend how much summer sunlight
45
46 exposure was required to maintain adequate vitamin D status in the winter, the RNI of 400 IU should
47
48 apply to all adults ⁹. It was not within SACN's remit to consider approaches to achieve this. It remains
49
50 a concern that those who are deemed most at risk of vitamin D deficiency do not get enough vitamin
51
52 D. Despite the RNI for vulnerable groups existing since 1991, with recommendation of vitamin D
53
54 supplements, it is clear that this message has not been reaching many in the 'at risk' groups. It is
55
56 likely that any voluntary fortification of foods by manufacturers would necessitate surcharges that
57
58
59
60
61

1 might render such items unaffordable to those most in need; and that mandatory fortification of
2 foods most likely to be consumed by different populations should be considered. Our data imply
3 that the amounts needed are small enough not to place any risk to those currently getting sufficient
4 vitamin D through a combination of summer sunlight and diet.
5
6

7
8
9
10 We did not find any influence of other nutrients, for example calcium, considered to be 'vitamin D
11 sparing'⁴⁵, or vitamin A; but the FFQ may be insufficiently sensitive to detect small differences. The
12 interaction of other nutrients with vitamin D may be more important in predicting health outcomes.
13
14 Other limitations of the RECALL study are that the women who took part could be different from
15 those randomised to the RCT, but we found no significant difference in 25OHD, nor the percentage
16 below the deficiency cut-off. Although it is possible that some women, despite their stating
17 otherwise, had taken vitamin D supplements since the study finished; it is unlikely that this applies
18 to everyone, as they had been presented with results showing that there was no benefit of vitamin D
19 supplementation on cardiovascular risk markers. If those on placebo had started taking vitamin D,
20 this would have narrowed the margins between the treatment groups. In either scenario, the
21 women would have had to purchase vitamin D supplements themselves to continue. The
22 generalisability of the study is restricted to outwardly healthy Caucasians in the UK, and highlights
23 the need for concentrating resources on ethnicities at increased risk of vitamin D deficiency.
24
25

26
27 The strengths are that the study was carried out at 57°N, with no UVB radiation between April and
28 October, and averaging less summer sunlight exposure than the rest of the UK³⁷. The daily doses of
29 400 IU and 1000 IU vitamin D3 are relevant to population recommendations, the former being the
30 current UK RNI (400IU), and well below recommended safe upper limits. All volunteers started the
31 original study in January-March, and the decay and RECALL visits were in the same month (March).
32
33 In addition, the improved methodology for measurement of vitamin D metabolites, with all samples
34 being analysed together, ensures robustness of the measurements.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 In conclusion, 400 IU (or 1000 IU) vitamin D3 taken daily for 1 year still showed benefits over placebo
2 2 years after the supplementation stopped, in terms of reducing the number of people with 25OHD
3 < 25 nmol/L. The benefit was no longer significant after 3 years. The findings support the RNI of 400
4 IU daily vitamin D in adults in order to protect the UK population from risk of vitamin D deficiency;
5 and appropriate risk management strategies should be implemented. It is recommended that
6 25OHD measurement by tandem mass spectrometry adopts a de-lipidation procedure to allow
7 better comparisons between studies and when using stored samples.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Competing Interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf.

JCYT, ADW, LSA and WDF declare no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. HMM and AG acknowledge part-support from UK Food Standards Agency, and the Department of Health for the submitted work, but no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

This work was funded partly by the UK Food Standards Agency, and the Department of Health . Any views expressed are the authors own. Original trial registration: Vitamin D effects on cardiovascular disease risk (VICtORy) study at controlled - trials.com as ISRCTN20328039 ([http://controlled - trials.com/ISRCTN20328039/](http://controlled-trials.com/ISRCTN20328039/)).

We wish to thank all the women volunteers taking part in this study; Karen Secombes, Minimol Paulose and Jenny Scott for assistance with venesection; Martin Allen, Health Protection Agency, Cambridge for help in standardising the UVA badges; Maciej Gryka for creating the algorithms used to extract the data from the UVA badges; and Hamish Macdonald for assistance in generating the figures.

Authors roles: HMM (principal investigator) had full access to all of the data in the study and takes responsibility for its integrity and the accuracy of the data analysis. She was involved in the study design, obtaining funding, study management, and the writing of the manuscript. AG and AW were responsible for the day-to-day running and cleaning of data for the VICtORy RECALL study, and the original VICtORy RCT, respectively. LSA provided statistical advice and interpretation. JT and WDF analysed and interpreted the measurements for vitamin D metabolites and PTH. All authors critically appraised the manuscript.

1 Role of the sponsor: The sponsor, Research and Innovation, University of Aberdeen, UK, was
2 responsible for confirming proper arrangements to initiate, manage, monitor, and finance this RCT
3
4 as designated by the Scottish Executive Health Department Research Governance Framework for
5
6 Health and Community Care and the Department of Health Research Governance Framework for
7
8 Health and Social Care 2nd Edition (2006)-Confirmation of the Role of Sponsor.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1 Characteristics of RECALL participants (measured in 2012 unless otherwise indicated)
according to treatment allocation for the original VICtORy RCT

Mean (SD)	Placebo	400 IU vitamin D3	1000 IU vitamin D3	P
n	52	49	58	
Age (y)	67.5 (2.1)	67.4 (1.8)	68.0 (2.2)	0.222
Weight (kg)	69.6 (11.3)	70.0 (12.7)	71.1 (11.1)	0.771
Lean mass (kg) *	38.6 (3.7)	38.3 (4.6)	38.5 (4.4)	0.804
Fat mass (kg) *	29.0 (8.0)	29.1 (8.8)	30.0 (8.4)	0.806
Systolic Blood Pressure (mm Hg)	128 (16)	129 (16)	127 (15)	0.842
Diastolic Blood Pressure (mm Hg)	75 (8)	75 (9)	76 (7)	0.926
n	50	47	54	
vitamin D (diet only)(μ g)	5.5 (3.6)	5.2 (2.9)	4.8 (3.5)	0.517
vitamin D (diet + supplements) (μ g)	6.3 (4.4)	6.1 (3.4)	6.7 (4.4)	0.786
Dietary calcium (mg)	1327 (441)	1242 (741)	1269 (630)	0.784
VDBP (μ g/L)	263 (90)	296 (97)	244 (89)	0.021
PTH (pmol/L)	5.6 (1.7)	5.2 (2.1)	5.0 (1.3)	0.223
n	52	49	58	
25OHD (nmol/L) at RCT start (in 2009)	36.1 (18.7)	33.3 (12.6)	33.2 (15.5)	0.559
25OHD (nmol/L) at end of	32.6 (15.6)	66.6 (20.6)	74.6 (20.1)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RCT (in 2010)				
1,25OH2D (pmol/L) at start of RCT **	135 (42)	138 (38)	132 (42)	0.700
1,25OH2D (pmol/L) at end of RCT **	127 (42)	145 (46)	134 (42)	0.098
n	46	49	55	
25OHD (nmol/L) at RCT start (after de-lipidation)	43.6 (21.1)	46.2 (19.2)	43.7 (21.7)	0.789
25OHD (nmol/L) at end of RCT (after de-lipidation)	43.6 (18.9)	84.8 (17.2)	91.1 (24.3)	<0.001
24,25OHD (nmol/L) at RCT start (after de-lipidation)	2.9 (1.9)	3.1 (1.5)	3.0 (2.0)	0.893
24,25OHD at end of RCT (after de-lipidation)	2.8 (1.5)	6.4 (1.6)	7.7 (2.7)	<0.001
Categories				
Time abroad > 1 month since RCT	14.3	20.8	9.3	0.254
Passive smoker (%)	7.8	4.2	12.1	0.336

* measured at V6 (end of RCT)

**1,25OH2D measured by immunoassay

Supplementary Table 1. Differences in characteristics, measured at randomization for the VICtORY RCT (in 2009), between RECALL participants and those who did return for the RECALL visits (in 2012)

Mean (SD)	RECALL	VICtORY non-returners	p
n	159	146	
Age (y)	64.7 (2.1)	64.5 (2.3)	0.499
Height (cm)	161 (6)	161 (6)	0.425
Weight (kg)	70.6 (11.1)	67.4 (12.8)	0.018
Grip strength	22.3 (4.8)	22.5 (4.9)	0.784
25OHD (nmol/L) *	34.3 (15.8)	33.4 (13.6)	0.915
1,25OH2D (pmol/L)**	139 (46)	137 (41)	0.714
n	158	137	
Dietary vitamin D (µg/d)	5.0 (2.7)	5.7 (4.8)	0.119
Dietary calcium (mg)	1272 (528)	1285 (482)	0.822
n	153	140	
Sunlight exposure baseline (SED/ week)	0.85 (0.92)	0.89 (1.18)	0.761
n	151	114	
Sunlight exposure july- august (SED/ week)	6.15 (5.02)	7.13 (10.03)	0.302

* 25OHD measured by the tandem mass spectrometry but no de-lipidation of samples

**1,25OH2D measured by immunoassay

SED standard erythemal dose (100 J m⁻²) estimated from polysulphone badges

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2 Mixed model analysis to determine predictors of (A) 25OHD and (B) 24,25(OH)2D following cessation of supplements.

Independent Variables	(A) 25OHD (nmol/L)			(B) 24,25OH2D (nmol/L)		
	Beta	95% CI	P	Beta		P
Model 1 (4-visit) (n 158)						
Constant	3.919	3.673-4.164	<0.001	1.264	1.112 to 1.415	<0.001
Visit						
Study end	0.493	0.349 to 0.636	<0.001	0.566	0.448 to 0.684	<0.001
+1 month	0.376	0.238 to 0.513	<0.001	0.476	0.368 to 0.585	<0.001
+2 year	0.123	0.036 to 0.210	0.006	0.132	0.046 to 0.217	0.003
+3 year	0					
Treatment group						
placebo	-0.745	-0.869 to -0.620	<0.001	-0.951	-1.090 to -0.811	<0.001
400 IU	-0.080	-0.208 to 0.048	0.216	-0.165	-0.306 to -0.024	0.022
1000 IU	0					
VDBP (µg/L)	0.736	0.216 to 1.255	0.006			
Dietary energy intake (J/d)	-0.030	-0.048 to -0.011	0.002			

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Holiday abroad yes no				0.170	0.067 to 0.274	0.001
UVB year (SED)	0.479 x 10 ⁻³	0.044 x 10 ⁻³ to 0.914 x 10 ⁻³	0.031			
Additional variables						
1,25OH2D (pmol/L)	2.334 x 10 ⁻³	1.266 x 10 ⁻³ to 3.403 x 10 ⁻³	<0.001	2.997 x 10 ⁻³	1.775 x10 ⁻³ to 4.218 x10 ⁻³	<0.001
PTH (pmol/L)	-0.039	-0.073 to -0.005	0.026	-0.068	-0.104 to -0.032	<0.001
Model 2a (2-visit) (n 151)						
Constant	4.158	3.862 to 4.634	<0.001	1.338	1.126 to 1.545	<0.001
Visit (+2 year vs +3 year)	0.082	0.020 to 0.144	0.010	0.133	0.048 to 0.218	0.002
Treatment group						
placebo	-0.203	-0.357 to -0.050	0.010	-0.273	-0.480 to -0.067	0.010
400 IU	-0.112	-0.273 to 0.049	0.172	-0.162	-0.372 to +0.049	0.132
1000 IU	0					
Supplements	+0.167	-0.321 to -0.013	0.034	0.356	0.151 to 0.561	0.001
VDBP ug/L	0.645	-0.002 to 1.292	0.051			
Holidays (days abroad)	+0.0038	0.0005 to 0.0071	0.025	0.0053	0.0008 to 0.0097	0.020

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Arm skin colour (ITA)	-0.0087	-0.0166 to -0.0009	0.029			
Additional variables						
1,25OH2D (pmol/L)	3.179 x 10 ⁻³ *	1.740 x 10 ⁻³ to 4.618 x 10 ⁻³	<0.001	4.203 x 10 ⁻³	2.271x10 ⁻³ to 6.135 x10 ⁻³	<0.001
PTH (pmol/L)	-0.045 *	-0.076 to -0.129	0.006	-0.058	-0.100 to -0.015	0.008
*VDBP, Supplements and Skin colour no longer significant predictors						
Model 2b (2-visit, sub-set) (n 73)						
Constant	4.168	3.897 to 4.456	<0.001	1.713	1.296 to 2.130	<0.001
Visit (+2 year vs +3 year)	0.133	0.053 to 0.213	0.001	0.176	0.060 to 0.292	0.003
Treatment group						
placebo	-0.176	-0.381 to 0.029	0.092	-0.319	-0.621 to -0.018	0.038
400 IU	-0.034	-0.247 to 0.179	0.751	-0.155	-0.468 to 0.157	0.326
1000 IU	0					
Supplements	0.420	0.203 to 0.636	<0.001	0.560	0.243 to 0.877	0.001
UVB-April-March	-0.001	-0.002 to +0.000	0.077 *	-0.0016	-0.0032 to 0.0001	0.061 *
Additional variable						
1,25OH2D (pmol/L)	3.800 x10 ⁻³	1.952 x10 ⁻³ to 5.648 x10 ⁻³	<0.001	3.698 x10 ⁻³	0.946 x10 ⁻³ to 6.450 x10 ⁻³	0.009
	* P=0.030 when additional variable added			* P=0.036 when additional variable added		

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Model 1. Repeated measures was based on final VICtORy visit, +1m, +2y, and +3y time-points and included the main outcome measures 25OHD and 24,25OH2D (log transformed). Repeated variables tested included weight, dietary vitamin D and other dietary nutrients, 1,25(OH)2D, and PTH. Fixed variables tested included: visit, original treatment group, supplement use (CLO), total days holiday, VDBP, SED from VICtORy, sunlight behaviour

Model 2a. Repeated measures was based on +2y and +3y time points only, and included the main outcome measurement. Repeated variables tested included weight, dietary vitamin D and other dietary nutrients, skin colour, 1,25(OH)2D, and PTH. Fixed variables tested included original treatment group, age, total days holiday, sunlight behaviour, VDBP

Model 2b. As for model 2a above but for the subset of women who undertook sunlight exposure measurements. Exposure to UVA and UVB were tested separately

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary Table 2 Characteristics of between women below and above thresholds for (A) 25OHD (25 nmol/L) and (B) 24,25OH2D (2.2 nmol/L) at the final RECALL visit

	<i>(A) 25OHD: 25 nmol/L</i>			<i>(C) 24,25OHD: 2.2 nmol/L</i>		
<i>Mean (SD)</i>	Below threshold n=25	Above threshold n=120	P	Below threshold n=48	Above threshold n=95	P
Age (y)	65.0 (2.3)	64.5 (2.0)	NS	64.8 (2.2)	64.5 (1.9)	NS
Weight (kg)	71.9 (18.4)	70.6 (10.7)	NS	71.0 (12.8)	70.2 (10.5)	NS
VDBP (ug/ml)	250 (91)	269 (93)	NS	265 (91)	266 (95)	NS
Energy intake (MJ/d)	9.18 (2.88)	8.97 (3.24)	NS	9.44 (4.21)	8.81 (2.56)	NS
Dietary fat (g/d)	82.5 (34.4)	81.8 (32.3)	NS	86.4 (40.5)	80.8 (29.8)	NS
Dietary protein (g/d)	92.3 (28.6)	92.1 (35.30)	NS	95.0 (41.5)	90.9 (30.5)	NS
Dietary vitamin D (ug/d)	5.5 (3.1)	5.1 (3.4)	NS	5.57 (3.5)	5.0 (3.3)	NS
Dietary calcium (mg/d)	1330 (608)	1247 (491)	NS	1299 (665)	1243 (420)	NS
UVB June (SED)	17.4	17.3	NS	17.9 (14.8)	17.3 (10.6)	NS
UVB July (SED)	23.0	20.4	NS	23.4 (19.5)	19.7 (14.5)	NS
UVB Aug (SED)	24.8	24.2	NS	24.2 (15.6)	24.2 (14.0)	NS
Holidays win12-spr13	11 (17)	19 (21)		15 (19)	20 (22)	

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

25OHD start V0	33.9 (15.7)	45.5 (20.0)	<0.01	35.4 (15.9)	47.9 (20.1)	<0.01
25OHD summer V3	72.2 (28.6)	82.1 (20.5)	NS	75.5 (24.8)	82.8 (19.9)	0.07
25OHD end V6	67.5 (38.1)	76.0 (27.1)	NS	66.8 (33.5)	78.3 (25.4)	0.04
Arm skin colour (ITA)	55.6 (6.1)	52.5 (5.4)	0.01	53.5 (5.8)	52.7 (5.4)	NS
1,25OH2D pmol/L V9	77.3 (35.2)	96.2 (35.2)	0.02	82.3 (29.4)	99.1 (37.2)	0.08
PTH pmol/L V9	5.5 (2.0)	5.3 (1.6)	NS	5.7 (1.9)	5.2 (1.5)	NS
<i>Categories</i>						
% in placebo, 400 IU and 1000 IU	44, 24, 32	31, 32, 37	NS	44, 25, 31	27, 35, 38	NS
Supplement user %	12.0	25.0	NS	12.5	28.4	0.03
Passive smoker	12.5	7.6	NS	6.4	9.5	NS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1 Participant flow diagram

Figure 2 Deficiency thresholds (A)25OHD (B) 24,25OH2D

Figure 3 Mean (A) 25OHD (new method) (B) 24,25OH2D (C) 1,25OH2D (D) PTH

Supplementary Figure 1 Monthly UV exposure throughout 2012-2013 in a subset of VICTORY RECALL

References

1. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017; **356**: i6583.
2. Bolland MJ, Avenell A. Do vitamin D supplements help prevent respiratory tract infections? *BMJ* 2017; **356**: j456.
3. Sattar N, Welsh P, Panarelli M, Forouhi NG. Increasing requests for vitamin D measurement: costly, confusing, and without credibility. *Lancet* 2012; **379**(9811): 95-6.
4. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. *The Lancet Diabetes & Endocrinology* 2014; **2**(1): 76-89.
5. Pludowski P, Holick MF, Pilz S, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. *Autoimmun Rev* 2013; **12**(10): 976-89.
6. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ* 2014; **348**: g2035.
7. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. *Lancet* 2014; **383**(9912): 146-55.
8. IOM, (Institute_of_Medicine). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.
9. SACN. Vitamin D and Health. London: TSO; Scientific Advisory Committee on Nutrition) (2016).
10. European_Food_Safety_Authority. Dietary references values for vitamin D. *EFSA Journal* 2016; **14**(10: 4547): 1-145.
11. Department_of_Health. Nutrition and bone health: with particular reference to calcium and vitamin D. London: HMSO; 1998.
12. Jones G. Pharmacokinetics of vitamin D toxicity. *Am J Clin Nutr* 2008; **88**(2): 582S-6S.
13. Vieth R. Vitamin D supplementation, 25-hydroxy vitamin D concentrations and safety. *Am J Clin Nutr* 1999; **69**: 842-56.
14. Mawer EB, Schaefer K, Lumb GA, Stanbury SW. The metabolism of isotopically labelled vitamin D3 in man: the influence of the state of vitamin D nutrition. *Clin Sci* 1971; **40**(1): 39-53.
15. Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. *Am J Clin Nutr* 2008; **87**(6): 1738-42.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
16. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *American Journal of Clinical Nutrition* 2001; **73**(2): 288-94.
 17. Gallagher JC, Sai A, Templin T, 2nd, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. *Ann Intern Med* 2012; **156**(6): 425-37.
 18. Macdonald HM, Wood AD, Aucott LS, et al. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 2013; **28**(10): 2202-13.
 19. Jones KS, Assar S, Harnpanich D, et al. 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. *J Clin Endocrinol Metab* 2014; **99**(9): 3373-81.
 20. Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. *The New England journal of medicine* 2013; **369**(21): 1991-2000.
 21. Nielson CM, Jones KS, Chun RF, et al. Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations. *J Clin Endocrinol Metab* 2016; **101**(5): 2226-34.
 22. Cashman KD, Hayes A, Galvin K, et al. Significance of serum 24,25-dihydroxyvitamin D in the assessment of vitamin D status: a double-edged sword? *Clin Chem* 2015; **61**(4): 636-45.
 23. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007; **357**(3): 266-81.
 24. Owens DJ, Tang JC, Bradley WJ, et al. Efficacy of High-Dose Vitamin D Supplements for Elite Athletes. *Med Sci Sports Exerc* 2017; **49**(2): 349-56.
 25. Tang JCWN, H.; Piec, I.; Washbourne, C.J.; Dutton, J.J.; Jackson, S.; Greeves, J.; Fraser, W.D. Reference intervals for serum 24,25-dihydroxyvitamin D and the ratio with 25-hydroxyvitamin D established using a newly developed LC-MS/MS method. *J Nutr Biochem* 2017; **46**: 21-9.
 26. Wood AD, Secombes KR, Thies F, et al. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. *J Clin Endocrinol Metab* 2012; **97**(10): 3557-68.
 27. Del Bino S, Sok J, Bessac E, Bernerd F. Relationship between skin response to ultraviolet exposure and skin color type. *Pigment Cell Res* 2006; **19**(6): 606-14.
 28. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. *Arch Dermatol* 1988; **124**(6): 869-71.
 29. Diffey BL. Ultraviolet radiation dosimetry with polysulphone film. In: Diffey BL, ed. *Radiation Measurement in Photobiology*. London: Academic Press; 1989: 135-59.
 30. Macdonald HM, Mavroeidi A, Aucott LA, et al. Skin color change in Caucasian postmenopausal women predicts summer-winter change in 25-hydroxyvitamin D: findings from the ANSAViD cohort study. *J Clin Endocrinol Metab* 2011; **96**(6): 1677-86.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
31. Mocanu V, Vieth R. Three-year follow-up of serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in nursing home residents who had received 12 months of daily bread fortification with 125 mug of vitamin D3. *Nutrition journal* 2013; **12**: 137.
 32. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr* 2003; **77**(1): 204-10.
 33. Jakobsen J, Maribo H, Bysted A, Sommer HM, Hels O. 25-hydroxyvitamin D3 affects vitamin D status similar to vitamin D3 in pigs--but the meat produced has a lower content of vitamin D. *Br J Nutr* 2007; **98**(5): 908-13.
 34. Heaney RP, Horst RL, Cullen DM, Armas LA. Vitamin D3 distribution and status in the body. *J Am Coll Nutr* 2009; **28**(3): 252-6.
 35. Heaney RP, Armas LA, French C. All-source basal vitamin D inputs are greater than previously thought and cutaneous inputs are smaller. *J Nutr* 2013; **143**(5): 571-5.
 36. Diffey BL. Modelling the seasonal variation of vitamin D due to sun exposure. *Br J Dermatol* 2010; **162**: 1342-8.
 37. Macdonald HM, Mavroeidi A, Fraser WD, et al. Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal women living at northerly latitudes: a major cause for concern? *Osteoporos Int* 2011; **22**(9): 2461-72.
 38. Holick MF. Sunlight, vitamin D and health: a D-lightful story. In: Bjertness E, ed. *Solar Radiation and Human Health*. Oslo: The Norwegian Academy of Science and Letters; 2008.
 39. Jamil NA, Gray SR, Fraser WD, Fielding S, Macdonald HM. The relationship between vitamin D status and muscle strength in young healthy adults from sunny climate countries currently living in the northeast of Scotland. *Osteoporos Int* 2017.
 40. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr* 2004; **80**(6 Suppl): 1678S-88S.
 41. Macdonald HM, Mavroeidi A, Barr RJ, Black AJ, Fraser WD, Reid DM. Vitamin D status in postmenopausal women living at higher latitudes in the UK in relation to bone health, overweight, sunlight exposure and dietary vitamin D. *Bone* 2008; **42**(5): 996-1003.
 42. Mavroeidi A, Aucott L, Black AJ, Fraser WD, Reid DM, Macdonald HM. Seasonal variation in 25(OH)D at Aberdeen (57 degrees N) and bone health indicators--could holidays in the sun and cod liver oil supplements alleviate deficiency? *Plos One* 2013; **8**(1): e53381.
 43. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* 2010; **376**(9736): 180-8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

44. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. *Am J Epidemiol* 2010; **171**(8): 903-8.

45. Lips P. Interaction between vitamin D and calcium. *Scand J Clin Lab Invest Suppl* 2012; **243**: 60-4.






Figure 1.

A



B









Figure Legends footnotes

Figure 2. Percentage of RECALL participants below selected deficiency cut-offs for vitamin D status

- A. Percentage of participants with 25OHD < 25 nmol/L for placebo, 400IU, and 1000IU daily vitamin D, respectively, was V0: 13, 8.2, 12.7; V1: 20.8, 0, 0; V2: 6.4, 0, 0; V3: 0, 0, 0; V4: 6.3, 0, 0; V5: 18.2, 0, 0; V6: 14.6, 0, 0; V7: 15.2, 0, 0; V8: 22, 4.2, 0; V9: 22.9, 13.3, 15.4
- B. Percentage of participants with 24,25OHD < 2.2 nmol/L for placebo, 400IU and 1000IU daily vitamin D, respectively, was V0: 45.7, 30.6, 40.0; V1: 52.1, 4.2, 1.9; V2: 25.5, 0, 0; V3: 6.8, 0, 0; V4: 18.8, 0, 0; V5: 29.5, 0, 0; V6: 47.9, 0, 0; V7: 50.0, 2.3, 1.9; V8: 42.0, 33.3, 12.3; V9: 44.7, 26.7, 29.4

Figure 3. Vitamin D metabolite (or PTH) concentration (mean and 95% confidence intervals), according to study visit (RECALL group only)

- A. Mean (SD) 25OHD in nmol/L from V0 to V9, respectively, was : 43.6 (21.1), 42.6 (21.8), 54.2 (24.6), 65.2 (19.4), 56.0 (21.1), 48.2 (21.8), 43.6 (18.9), 40.4 (17.0), 43.2 (20.8), 41.5 (20.4) for placebo; 46.2 (19.2), 73.5 (16.5), 80.6 (17.0), 82.7 (18.5), 85.3 (18.2), 84.2 (18.2), 84.8 (17.2), 72.5 (17.3), 49.2 (22.1), 45.5 (19.8) for 400 IU vitamin D; and 43.7 (21.7), 73.2 (18.5), 82.1 (18.8), 89.8 (20.9), 88.8 (20.3), 88.8 (23.3), 91.1 (24.3), 80.7 (17.0), 51.3 (17.4), 46.7 (18.5) for 1000 IU vitamin D.
- B. Mean (SD) 24,25OHD in nmol/L from V0 to V9, respectively, was : 2.9 (1.9), 2.7 (1.7), 3.4 (1.8), 4.7 (2.0), 4.2 (2.2), 3.3 (1.8), 2.8 (1.5), 2.6 (1.3), 3.2 (2.1), 3.0 (1.8) for placebo; 3.1 (1.5), 5.0 (1.6), 6.1 (1.6), 6.4 (1.6), 6.6 (1.6), 6.3 (1.6), 6.4 (1.6), 5.8 (1.7), 3.7 (2.2), 3.2 (1.9) for 400 IU vitamin D; and 3.0 (2.0), 5.8 (1.9), 6.9 (2.1), 7.7 (2.4), 7.8 (2.4), 8.0 (2.9), 7.7 (2.7), 7.0 (2.2), 4.4 (2.3), 3.5 (1.7) for 1000 IU vitamin D.
- C. Mean (SD) 1,25OHD in pmol/L for V7, V8 and V9, respectively, was : 90 (37), 94 (33), 89 (36) for placebo; 104 (37), 100 (34), 93 (32) for 400 IU vitamin D; and 95 (37), 93 (34), 99 (39) for 1000 IU vitamin D
- D. Mean (SD) PTH for V0, V6, V8 and V9, respectively, was : 5.1 (1.2), 5.0 (1.1), 5.6 (1.7), 5.6 (1.6) for placebo; 4.8 (1.5), 4.5 (1.2), 5.2 (2.1), 5.5 (2.0) for 400 IU vitamin D; and 5.2 (1.3), 4.3 (1.0), 5.0 (1.3), 5.0 (1.3) for 1000 IU vitamin D


Supplementary Figure 1. Daily UV exposure according to the month the badges were worn

- A. Median (IQR) for UVB exposure in SED each month from April 2012 to July 2013 (from April 2012 to March 2013, average n=143; from April 2013-July 2013, average n=74): 0.2 (0.3), 0.7


(0.8), 0.5 (0.4), 0.5 (0.6), 0.7 (0.7), 0.4 (0.5), 0.1 (0.2), 0.0 (0.1), 0.0 (0.0), 0.0 (0.0), 0.1 (0.1),
0.1 (0.1), 0.4 (0.4), 0.7 (0.9), 0.7 (0.7), 1.1 (0.9).

- B. Median (IQR) for UVA exposure in SED each month from August 2012 to July 2013 (average
n 77) : 578 (945), 534 (1008), 152 (306), 56 (100), 18 (24), 24 (33), 45 (67), 105 (219), 227
(566), 530 (993), 613 (862), 848 (1388).

UVB



UVA



Supplementary Table 1. Differences in characteristics, measured at randomization for the VICtORY RCT (in 2009), between RECALL participants and those who did return for the RECALL visits (in 2012)

Mean (SD)	RECALL	VICtORy non-returners	p
n	159	146	
Age (y)	64.7 (2.1)	64.5 (2.3)	0.499
Height (cm)	161 (6)	161 (6)	0.425
Weight (kg)	70.6 (11.1)	67.4 (12.8)	0.018
Grip strength	22.3 (4.8)	22.5 (4.9)	0.784
25OHD (nmol/L) *	34.3 (15.8)	33.4 (13.6)	0.915
1,25OH2D (pmol/L)**	139 (46)	137 (41)	0.714
n	158	137	
Dietary vitamin D (µg/d)	5.0 (2.7)	5.7 (4.8)	0.119
Dietary calcium (mg)	1272 (528)	1285 (482)	0.822
n	153	140	
Sunlight exposure baseline (SED/ week)	0.85 (0.92)	0.89 (1.18)	0.761
n	151	114	
Sunlight exposure july- august (SED/ week)	6.15 (5.02)	7.13 (10.03)	0.302

* 25OHD measured by the tandem mass spectrometry but no de-lipidation of samples

**1,25OH2D measured by immunoassay

SED standard erythemal dose (100 J m⁻²) estimated from polysulphone badges

Supplementary Table 2 Characteristics of between women below and above thresholds for (A) 25OHD (25 nmol/L) and (B) 24,25OHD (2.2 nmol/L) at the final RECALL visit

Mean (SD)	(A) 25OHD: 25 nmol/L		P	(A) 24,25OHD: 2.2 nmol/L		P
	Below threshold n=25	Above threshold n=120		Below threshold n=48	Above threshold n=95	
Age (y)	65.0 (2.3)	64.5 (2.0)	NS	64.8 (2.2)	64.5 (1.9)	NS
Weight (kg)	71.9 (18.4)	70.6 (10.7)	NS	71.0 (12.8)	70.2 (10.5)	NS
VDBP (ug/ml)	250 (91)	269 (93)	NS	265 (91)	266 (95)	NS
Energy intake (MJ/d)	9.18 (2.88)	8.97 (3.24)	NS	9.44 (4.21)	8.81 (2.56)	NS
Dietary fat (g/d)	82.5 (34.4)	81.8 (32.3)	NS	86.4 (40.5)	80.8 (29.8)	NS
Dietary protein (g/d)	92.3 (28.6)	92.1 (35.30)	NS	95.0 (41.5)	90.9 (30.5)	NS
Dietary vitamin D (ug/d)	5.5 (3.1)	5.1 (3.4)	NS	5.57 (3.5)	5.0 (3.3)	NS
Dietary calcium (mg/d)	1330 (608)	1247 (491)	NS	1299 (665)	1243 (420)	NS
UVB June (SED)	17.4	17.3	NS	17.9 (14.8)	17.3 (10.6)	NS
UVB July (SED)	23.0	20.4	NS	23.4 (19.5)	19.7 (14.5)	NS
UVB Aug (SED)	24.8	24.2	NS	24.2 (15.6)	24.2 (14.0)	NS
Holidays win12-spr13	11 (17)	19 (21)		15 (19)	20 (22)	

25OHD start V0	33.9 (15.7)	45.5 (20.0)	<0.01	35.4 (15.9)	47.9 (20.1)	<0.01
25OHD summer V3	72.2 (28.6)	82.1 (20.5)	NS	75.5 (24.8)	82.8 (19.9)	0.07
25OHD end V6	67.5 (38.1)	76.0 (27.1)	NS	66.8 (33.5)	78.3 (25.4)	0.04
Arm skin colour (ITA)	55.6 (6.1)	52.5 (5.4)	0.01	53.5 (5.8)	52.7 (5.4)	NS
1,25OH ₂ D pmol/L V9	77.3 (35.2)	96.2 (35.2)	0.02	82.3 (29.4)	99.1 (37.2)	0.08
PTH pmol/L V9	5.5 (2.0)	5.3 (1.6)	NS	5.7 (1.9)	5.2 (1.5)	NS
<i>Categories</i>						
% in placebo, 400 IU and 1000 IU	44, 24, 32	31, 32, 37	NS	44, 25, 31	27, 35, 38	NS
Supplement user %	12.0	25.0	NS	12.5	28.4	0.03
Passive smoker	12.5	7.6	NS	6.4	9.5	NS